PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 10, 2026Asian Pacific Journal of Cancer Prevention0 citationsOpen Access

Quinoxaline as Dual Modulators of Apoptotic Regulators Bcl-2 and Bax: A Combined In Vitro and In Silico Anticancer Approach

CDCecileya Jasmin Meshak DhanashekaranVVVinod Prabhu VenugopalNCNivetha Chokkalingam

Key Points

  • This research aims to explore the dual action of quinoxaline on apoptotic regulators Bcl-2 and Bax to enhance cancer cell death.
  • Conducted in vitro experiments to assess antioxidant activity and apoptotic effects of quinoxaline.
  • Utilized in silico docking simulations to evaluate interaction between quinoxaline and apoptotic regulators.
  • Analyzed the effects on Bcl-2 inhibition and Bax activation.
  • Quinoxaline exhibited significant antioxidant activity.
  • It was found to inhibit the anti-apoptotic protein Bcl-2.
  • Simultaneously, quinoxaline promoted the activity of the pro-apoptotic protein Bax, leading to increased apoptosis.

Abstract

Quinoxaline demonstrated significant antioxidant activity and potential pro-apoptotic effects by targeting key apoptotic regulators. The docking results suggest that quinoxaline could inhibit anti-apoptotic Bcl-2 while promoting the activity of the pro-apoptotic Bax, thereby inducing apoptosis and highlighting its potential as a promising anticancer agent.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Dhanashekaran et al. (2026) studied this question.

synapsesocial.com/papers/69af95b470916d39fea4d8dehttps://doi.org/10.31557/apjcp.2026.27.3.1017
Ask AI
Helpful
Bookmark
Share
View Full Paper